Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I/II study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and initial efficacy of intravitreal injection of OCUL101 in patients with neovascular age-related macular degeneration, diabetic macular edema, and geographic atrophy secondary to age-related macular degeneration, involving dose escalation and dose extension.

Next Previous
Trial Profile

A phase I/II study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and initial efficacy of intravitreal injection of OCUL101 in patients with neovascular age-related macular degeneration, diabetic macular edema, and geographic atrophy secondary to age-related macular degeneration, involving dose escalation and dose extension.

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs OCUL 101 (Primary) ; Aflibercept; Faricimab
  • Indications Age-related macular degeneration; Diabetic macular oedema; Dry macular degeneration
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Shenzhen Oculgen Biomedical Technology

Most Recent Events

  • 20 Apr 2026 New trial record
  • 24 Mar 2026 According to an Oculgen media release, completed the Phase 1b multiple ascending dose (MAD) high-dose cohort of monthly intravitreal (IVT) injections in China,All patients in P1b trial had a medical history of multiple prior anti-VEGF intravitreal injections for nAMD. The Phase 1b cohort completion has provided valuable safety and efficacy data to support the advancement to Phase II trials.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top